Abstract

DIAZ-DIAZ, CL; VINA-ROMERO, MM; MERINO-ALONSO, J  and  GUTIERREZ-NICOLAS, F. Pegylated interferon alfa-2a as a treatment opportunity for pregnant patients with chronic myeloid leukemia. Rev. OFIL·ILAPHAR [online]. 2021, vol.31, n.4, pp.429-430.  Epub Sep 19, 2022. ISSN 1699-714X.  https://dx.doi.org/10.4321/s1699-714x20210004000018.

Chronic myeloid leukemia (CML) is a disease that can affect women of childbearing age with the intention of having children. The standard treatment for this neoplastic disease is tyrosine kinase inhibitors (TKIs), however, they are not indicated in case of pregnancy. The ideal pharmacotherapeutic strategy is to attempt discontinuation of treatment in suitable candidate patients who have undergone 3 years of TKI treatment and at least 2 years in a higher molecular response.

We present the case of a 33-year-old patient diagnosed with CML who,after 3 years of treatment with dasatinib, decides to get pregnant. A therapeutic discontinuation approach is attempted, but progression of the disease occurs before conception, which is controlled by pegylated interferon alpha-2a and is maintained during pregnancy. After the baby is born, dasatinib treatment is restarted and a higher molecular response is achieved again.

Keywords : Tyrosine kinase inhibitors; dasatinib; discontinuation; major/complete molecular response; chronic myeloid leukemia.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )